Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03753-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Mary Jo Lechowicz und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Winship Cancer Institute, Emory University, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Transplantation, Homologous. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin Pharmaceutical Development.
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapy for patients with T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), adult T-cell lymphoma (ATL), and peripheral T-cell lymphoma (PTCL). Mogamulizumab is an anti-CCR4 antibody that has been associated with an increased risk of transplant-related complications in retrospective analyses of ATL, particularly when administered within 50 days before transplantation. This post hoc analysis of 3 clinical trials examined safety and outcome data for 32 patients with CTCL ( n = 23), ATL ( n = 7), or PTCL ( n = 2) who underwent allo-HSCT after mogamulizumab treatment. Overall, 22 patients (69%) were known to have graft-versus-host disease (GVHD), 8 patients (25%) did not report GVHD, and 2 patients (6%) had unknown GVHD status. Fourteen patients with known GVHD underwent transplantation between 50 and 365 days after their last dose of mogamulizumab, while 2 underwent transplantation within 50 days after treatment. Based on this limited evidence, GVHD was not associated with the time interval from last mogamulizumab dose to transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Winship Cancer Institute, Emory University, Atlanta, GA, USA.
- Medical Affairs Oncology, Kyowa Kirin, Inc, Princeton, NJ, USA.
- Medical Affairs Oncology, Kyowa Kirin, Inc, Princeton, NJ, USA. robert.ristuccia.bt@kyowakirin.com.
- Medical Sciences, Kyowa Kirin, Inc, Princeton, NJ, USA.
Förderung
- Kyowa Kirin Pharmaceutical Development
Zitieren
APA
Lechowicz, M. J., Smith, C., Ristuccia, R., & Dwyer, K. (2024). Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03753-9
Vancouver
Lechowicz MJ, Smith C, Ristuccia R, Dwyer K. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03753-9
BibTeX
@article{Lechowicz2024,
author = {Lechowicz, Mary Jo and Smith, Christy and Ristuccia, Robert and Dwyer, Karen},
title = {Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03753-9}
}
EUVIMED